Nasdaq biotech news
-
Capricor’s Deramiocel Voted Down 9-3 by FDA Advisory Panel
Nine advisory committee members looked at the same trial data Capricor called a win and voted against it. The 9-3 result on July 29 didn’t kill Capricor’s Duchenne muscular dystrophy program, but it added a real question mark to a therapy the company insists already cleared its bar. INmune Bio spent the same stretch doing…
-
Capricor Plunges 67% on FDA Panel News Ahead of DMD Vote
Capricor Therapeutics lost roughly two-thirds of its market value on Monday. Not from a failed trial. From a document explaining what a panel might discuss on Wednesday. Curis and Autonomix Medical had smaller, quieter reactions of their own to their own news this week, one up, one down, each worth understanding on its own terms.…
-
CareDx Jumps on Medicare Win, OKYO Pharma Funds Phase 3 Trial
A federal coverage policy that took a year to finalize added more than $200 million to CareDx’s market value in a single trading session. Nothing about the underlying science changed. The paperwork did. Two much smaller names had quieter weeks of their own: one locked in the cash to finish its pivotal trial, the other…